介绍专利申请中涉及的序列表问题

2015-05-12 MedSci MedSci原创

情况说明:1)当发明的技术方案属于生物技术领域时,特别是当技术方案中涉及包含一个或多个核苷酸或者氨基酸序列时,《专利法》对此做了明确的规定。2)《专利法》规定,当发明涉及由10个或更多核苷酸组成的核苷酸序列,或由4个或更多L-氨基酸组成的蛋白质或肽的氨基酸序列时,应递交符合规定的序列表。3)参照的标准为国家知识产权局发布的《核苷酸和/或氨基酸序列表和序列表电子文件标准》。4)序列表应在提交的说

情况说明:

1)当发明的技术方案属于生物技术领域时,特别是当技术方案中涉及包含一个或多个核苷酸或者氨基酸序列时,《专利法》对此做了明确的规定。

2)《专利法》规定,当发明涉及由10个或更多核苷酸组成的核苷酸序列,或由4个或更多L-氨基酸组成的蛋白质或肽的氨基酸序列时,应递交符合规定的序列表。

3)参照的标准为国家知识产权局发布的《核苷酸和/或氨基酸序列表和序列表电子文件标准》。

4)序列表应在提交的说明书的最后页以单独页面呈现,同时提交含有该序列表的计算机可读形式副本。

请见如下介绍:

 

(一)序列表不包括的内容:

1)提供的序列表,不包括支链序列。

2)提供的序列表,不包括具有少于4个特别定义的核苷酸或氨基酸的序列。

3)提供的序列表,不包括附录1之表1-4以外的核苷酸或氨基酸的序列。

4)提供的氨基酸序列表,不包括存在于天然蛋白质中的D-氨基酸。

 

(二)序列表包含的内容:

1)提供的序列表,是非支链核苷酸序列,或非支链氨基酸序列。

2)核苷酸,只包括附录1之表1列出的符号所表示的核苷酸;表2中列出的符号用于表达核苷酸的修饰形式。核苷酸的修饰形式,不得在核苷酸序列中直接使用表2中的符号表示。

3)氨基酸,只包括附录1之表3中的存在于天然蛋白质中的L-氨基酸;表4中列出的符号用于表达氨基酸的修饰形式。氨基酸的修饰形式,不得在氨基酸序列中直接使用表4中的符号表示。

 

(三)序列表格式要求:

1)序列表的格式要求,应有数字标识符,数字标识符之后是相应的具体内容。

2)纯核苷酸序列,核苷酸序列每行最多60个核苷酸碱基,每10个核苷酸碱基后空一格;该行的最后是该行最后一个碱基的编号。

3)纯氨基酸序列,对于氨基酸序列,蛋白质或肽序列中的氨基酸应当从左到右以氨基到羧基的方向列出;序列中不应当出现氨基或羧基基团。氨基酸序列每行最多16个氨基酸,每个氨基酸之间空一格。

4)核苷酸序列和与它对应的氨基酸序列,对应于其编码的氨基酸的核苷酸序列的碱基应当以“三联体”密码子列出,每个密码子之间应当空一格;对应于核苷酸序列的编码部分的氨基酸可以直接列于相应密码子的下方;对于该氨基酸序列,应当在第一个氨基酸的下面标注上编号1,然后每隔5个氨基酸在其下面标注上该氨基酸的编号。

 

(四)数字标识符

数字标识符:由尖括号<>括起来的代表特定内容数据项的三位数字。

<110>表示申请人的姓名或名称

<120>表示发明名称

<130>表示案卷参考号

<140>表示专利申请号

<141>表示专利申请日

<150>表示优先权号

<151>表示优先权日

<170>表示序列表电子文件的软件版本信息

<160>表示序列表中序列的个数

<210>表示序列标识符,在序列表中,每个序列应当有独立的、唯一的序列标识符,它应当从1开始并逐一增加。序列标识符表示每个序列在序列表中的序号。

<211>表示序列的长度

<212>表示序列的类型,DNARNAPRT三种类型。

<213>表示生物体

<220>-<223>表示序列中特征部分的内容

<221>表示特征名称/关键词

<222>表示应当标明特征的位置

<223>表示应当表述序列中与特征有关的其它相关信息

<300>-<312>表示出版公开信息(出版公开信息是非强制性的内容)

<300>表示公开出版信息

<301>表示该文献作者的姓名

<302>表示出版物中该文献的题目

<303>表示公开出版物的杂志名称

<304>表示公开出版物的卷号

<305>表示公开出版物的出版号

<306>表示该文献的起始-终止页码

<307>表示该公开出版物的出版日期

<308>表示该文献在该数据库中的登记号

<309>表示该文献录入该数据库的日期

<310>表示专利公开号

<311>表示专利申请日

<312>表示专利公开日

<400>表示核苷酸序列和/或氨基酸序列

 

(五)序列表的编写与提交

1)申请人在形成序列表电子文件时,可使用国家知识产权局专利局提供的序列表编辑软件来形成;也可以使用其它专利组织提供的软件(例如欧洲专利局提供的Patentin)来形成;还可以使用任何纯文本文件编辑软件来形成。

2)非电子申请途径的提交方法

序列表是一种纯文本文件,应记录在CD-ROM光盘或3.5英寸软盘上提交,要求在根目录下,有且仅有一个后缀名为“.SEQ”的纯文本文件,也可以为“.TXT”

3)电子申请途径的提交方法

CPC客户端上的附加文档栏内选择增加,增加对话框的右下角有个链接,点击里面有可读载体项。把已经制作好的TXT文本文档格式的序列表导入即可。

 

(六)附录1核苷酸和氨基酸符号和特征关键词表

1 核苷酸表

2 经修饰的核苷酸表

3 三字母表示的氨基酸表

4 经修饰的和不常用的氨基酸表

5 与核苷酸序列相关的特征关键词表

6 与蛋白质序列相关的特征关键词表

附录1中的表1至表6中的具体内容,以及其他详细法条请见链接

《核苷酸和/或氨基酸序列表和序列表电子文件标准》http://www.sipo.gov.cn/zcfg/flfg/bz/hybz/201403/t20140319_919629.html

(七)序列表样例

说明:带颜色部分为小编添加的批注。





版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (12)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=56212, encodeId=36fc56212c6, content=感谢分享~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:05:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56213, encodeId=5de55621333, content=感谢分享~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:05:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56214, encodeId=8fc356214dc, content=感谢分享~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:05:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56208, encodeId=716756208a9, content=嗯,, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:04:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56209, encodeId=3d945620911, content=嗯,, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:04:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56210, encodeId=a91e56210e4, content=以前很少接触,不懂,了解下……, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:04:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56211, encodeId=86d95621130, content=以前很少接触,不懂,了解下……, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:04:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1704910, encodeId=1d041e04910f7, content=<a href='/topic/show?id=71742062668' target=_blank style='color:#2F92EE;'>#专利申请#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20626, encryptionId=71742062668, topicName=专利申请)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e7a30885975, createdName=zhangjingnwpu, createdTime=Fri May 29 08:33:00 CST 2015, time=2015-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046537, encodeId=768f204653edc, content=<a href='/topic/show?id=7bca4923406' target=_blank style='color:#2F92EE;'>#序列表#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49234, encryptionId=7bca4923406, topicName=序列表)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce68183, createdName=xiongke010, createdTime=Wed Nov 11 18:33:00 CST 2015, time=2015-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=31797, encodeId=40c731e972b, content=第一次看专利的知识,收益了, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=01621631568, createdName=飞翔9899, createdTime=Thu Jul 09 11:04:00 CST 2015, time=2015-07-09, status=1, ipAttribution=)]
    2016-01-12 medsic

    感谢分享~~

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=56212, encodeId=36fc56212c6, content=感谢分享~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:05:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56213, encodeId=5de55621333, content=感谢分享~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:05:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56214, encodeId=8fc356214dc, content=感谢分享~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:05:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56208, encodeId=716756208a9, content=嗯,, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:04:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56209, encodeId=3d945620911, content=嗯,, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:04:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56210, encodeId=a91e56210e4, content=以前很少接触,不懂,了解下……, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:04:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56211, encodeId=86d95621130, content=以前很少接触,不懂,了解下……, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:04:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1704910, encodeId=1d041e04910f7, content=<a href='/topic/show?id=71742062668' target=_blank style='color:#2F92EE;'>#专利申请#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20626, encryptionId=71742062668, topicName=专利申请)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e7a30885975, createdName=zhangjingnwpu, createdTime=Fri May 29 08:33:00 CST 2015, time=2015-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046537, encodeId=768f204653edc, content=<a href='/topic/show?id=7bca4923406' target=_blank style='color:#2F92EE;'>#序列表#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49234, encryptionId=7bca4923406, topicName=序列表)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce68183, createdName=xiongke010, createdTime=Wed Nov 11 18:33:00 CST 2015, time=2015-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=31797, encodeId=40c731e972b, content=第一次看专利的知识,收益了, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=01621631568, createdName=飞翔9899, createdTime=Thu Jul 09 11:04:00 CST 2015, time=2015-07-09, status=1, ipAttribution=)]
    2016-01-12 medsic

    感谢分享~~

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=56212, encodeId=36fc56212c6, content=感谢分享~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:05:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56213, encodeId=5de55621333, content=感谢分享~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:05:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56214, encodeId=8fc356214dc, content=感谢分享~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:05:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56208, encodeId=716756208a9, content=嗯,, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:04:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56209, encodeId=3d945620911, content=嗯,, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:04:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56210, encodeId=a91e56210e4, content=以前很少接触,不懂,了解下……, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:04:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56211, encodeId=86d95621130, content=以前很少接触,不懂,了解下……, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:04:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1704910, encodeId=1d041e04910f7, content=<a href='/topic/show?id=71742062668' target=_blank style='color:#2F92EE;'>#专利申请#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20626, encryptionId=71742062668, topicName=专利申请)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e7a30885975, createdName=zhangjingnwpu, createdTime=Fri May 29 08:33:00 CST 2015, time=2015-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046537, encodeId=768f204653edc, content=<a href='/topic/show?id=7bca4923406' target=_blank style='color:#2F92EE;'>#序列表#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49234, encryptionId=7bca4923406, topicName=序列表)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce68183, createdName=xiongke010, createdTime=Wed Nov 11 18:33:00 CST 2015, time=2015-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=31797, encodeId=40c731e972b, content=第一次看专利的知识,收益了, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=01621631568, createdName=飞翔9899, createdTime=Thu Jul 09 11:04:00 CST 2015, time=2015-07-09, status=1, ipAttribution=)]
    2016-01-12 medsic

    感谢分享~~

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=56212, encodeId=36fc56212c6, content=感谢分享~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:05:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56213, encodeId=5de55621333, content=感谢分享~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:05:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56214, encodeId=8fc356214dc, content=感谢分享~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:05:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56208, encodeId=716756208a9, content=嗯,, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:04:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56209, encodeId=3d945620911, content=嗯,, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:04:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56210, encodeId=a91e56210e4, content=以前很少接触,不懂,了解下……, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:04:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56211, encodeId=86d95621130, content=以前很少接触,不懂,了解下……, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:04:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1704910, encodeId=1d041e04910f7, content=<a href='/topic/show?id=71742062668' target=_blank style='color:#2F92EE;'>#专利申请#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20626, encryptionId=71742062668, topicName=专利申请)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e7a30885975, createdName=zhangjingnwpu, createdTime=Fri May 29 08:33:00 CST 2015, time=2015-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046537, encodeId=768f204653edc, content=<a href='/topic/show?id=7bca4923406' target=_blank style='color:#2F92EE;'>#序列表#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49234, encryptionId=7bca4923406, topicName=序列表)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce68183, createdName=xiongke010, createdTime=Wed Nov 11 18:33:00 CST 2015, time=2015-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=31797, encodeId=40c731e972b, content=第一次看专利的知识,收益了, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=01621631568, createdName=飞翔9899, createdTime=Thu Jul 09 11:04:00 CST 2015, time=2015-07-09, status=1, ipAttribution=)]
    2016-01-12 medsic

    嗯,

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=56212, encodeId=36fc56212c6, content=感谢分享~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:05:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56213, encodeId=5de55621333, content=感谢分享~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:05:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56214, encodeId=8fc356214dc, content=感谢分享~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:05:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56208, encodeId=716756208a9, content=嗯,, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:04:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56209, encodeId=3d945620911, content=嗯,, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:04:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56210, encodeId=a91e56210e4, content=以前很少接触,不懂,了解下……, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:04:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56211, encodeId=86d95621130, content=以前很少接触,不懂,了解下……, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:04:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1704910, encodeId=1d041e04910f7, content=<a href='/topic/show?id=71742062668' target=_blank style='color:#2F92EE;'>#专利申请#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20626, encryptionId=71742062668, topicName=专利申请)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e7a30885975, createdName=zhangjingnwpu, createdTime=Fri May 29 08:33:00 CST 2015, time=2015-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046537, encodeId=768f204653edc, content=<a href='/topic/show?id=7bca4923406' target=_blank style='color:#2F92EE;'>#序列表#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49234, encryptionId=7bca4923406, topicName=序列表)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce68183, createdName=xiongke010, createdTime=Wed Nov 11 18:33:00 CST 2015, time=2015-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=31797, encodeId=40c731e972b, content=第一次看专利的知识,收益了, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=01621631568, createdName=飞翔9899, createdTime=Thu Jul 09 11:04:00 CST 2015, time=2015-07-09, status=1, ipAttribution=)]
    2016-01-12 medsic

    嗯,

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=56212, encodeId=36fc56212c6, content=感谢分享~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:05:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56213, encodeId=5de55621333, content=感谢分享~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:05:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56214, encodeId=8fc356214dc, content=感谢分享~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:05:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56208, encodeId=716756208a9, content=嗯,, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:04:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56209, encodeId=3d945620911, content=嗯,, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:04:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56210, encodeId=a91e56210e4, content=以前很少接触,不懂,了解下……, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:04:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56211, encodeId=86d95621130, content=以前很少接触,不懂,了解下……, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:04:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1704910, encodeId=1d041e04910f7, content=<a href='/topic/show?id=71742062668' target=_blank style='color:#2F92EE;'>#专利申请#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20626, encryptionId=71742062668, topicName=专利申请)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e7a30885975, createdName=zhangjingnwpu, createdTime=Fri May 29 08:33:00 CST 2015, time=2015-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046537, encodeId=768f204653edc, content=<a href='/topic/show?id=7bca4923406' target=_blank style='color:#2F92EE;'>#序列表#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49234, encryptionId=7bca4923406, topicName=序列表)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce68183, createdName=xiongke010, createdTime=Wed Nov 11 18:33:00 CST 2015, time=2015-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=31797, encodeId=40c731e972b, content=第一次看专利的知识,收益了, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=01621631568, createdName=飞翔9899, createdTime=Thu Jul 09 11:04:00 CST 2015, time=2015-07-09, status=1, ipAttribution=)]
    2016-01-12 medsic

    以前很少接触,不懂,了解下……

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=56212, encodeId=36fc56212c6, content=感谢分享~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:05:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56213, encodeId=5de55621333, content=感谢分享~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:05:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56214, encodeId=8fc356214dc, content=感谢分享~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:05:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56208, encodeId=716756208a9, content=嗯,, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:04:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56209, encodeId=3d945620911, content=嗯,, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:04:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56210, encodeId=a91e56210e4, content=以前很少接触,不懂,了解下……, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:04:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56211, encodeId=86d95621130, content=以前很少接触,不懂,了解下……, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:04:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1704910, encodeId=1d041e04910f7, content=<a href='/topic/show?id=71742062668' target=_blank style='color:#2F92EE;'>#专利申请#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20626, encryptionId=71742062668, topicName=专利申请)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e7a30885975, createdName=zhangjingnwpu, createdTime=Fri May 29 08:33:00 CST 2015, time=2015-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046537, encodeId=768f204653edc, content=<a href='/topic/show?id=7bca4923406' target=_blank style='color:#2F92EE;'>#序列表#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49234, encryptionId=7bca4923406, topicName=序列表)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce68183, createdName=xiongke010, createdTime=Wed Nov 11 18:33:00 CST 2015, time=2015-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=31797, encodeId=40c731e972b, content=第一次看专利的知识,收益了, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=01621631568, createdName=飞翔9899, createdTime=Thu Jul 09 11:04:00 CST 2015, time=2015-07-09, status=1, ipAttribution=)]
    2016-01-12 medsic

    以前很少接触,不懂,了解下……

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=56212, encodeId=36fc56212c6, content=感谢分享~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:05:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56213, encodeId=5de55621333, content=感谢分享~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:05:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56214, encodeId=8fc356214dc, content=感谢分享~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:05:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56208, encodeId=716756208a9, content=嗯,, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:04:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56209, encodeId=3d945620911, content=嗯,, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:04:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56210, encodeId=a91e56210e4, content=以前很少接触,不懂,了解下……, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:04:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56211, encodeId=86d95621130, content=以前很少接触,不懂,了解下……, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:04:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1704910, encodeId=1d041e04910f7, content=<a href='/topic/show?id=71742062668' target=_blank style='color:#2F92EE;'>#专利申请#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20626, encryptionId=71742062668, topicName=专利申请)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e7a30885975, createdName=zhangjingnwpu, createdTime=Fri May 29 08:33:00 CST 2015, time=2015-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046537, encodeId=768f204653edc, content=<a href='/topic/show?id=7bca4923406' target=_blank style='color:#2F92EE;'>#序列表#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49234, encryptionId=7bca4923406, topicName=序列表)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce68183, createdName=xiongke010, createdTime=Wed Nov 11 18:33:00 CST 2015, time=2015-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=31797, encodeId=40c731e972b, content=第一次看专利的知识,收益了, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=01621631568, createdName=飞翔9899, createdTime=Thu Jul 09 11:04:00 CST 2015, time=2015-07-09, status=1, ipAttribution=)]
  9. [GetPortalCommentsPageByObjectIdResponse(id=56212, encodeId=36fc56212c6, content=感谢分享~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:05:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56213, encodeId=5de55621333, content=感谢分享~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:05:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56214, encodeId=8fc356214dc, content=感谢分享~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:05:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56208, encodeId=716756208a9, content=嗯,, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:04:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56209, encodeId=3d945620911, content=嗯,, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:04:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56210, encodeId=a91e56210e4, content=以前很少接触,不懂,了解下……, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:04:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56211, encodeId=86d95621130, content=以前很少接触,不懂,了解下……, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:04:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1704910, encodeId=1d041e04910f7, content=<a href='/topic/show?id=71742062668' target=_blank style='color:#2F92EE;'>#专利申请#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20626, encryptionId=71742062668, topicName=专利申请)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e7a30885975, createdName=zhangjingnwpu, createdTime=Fri May 29 08:33:00 CST 2015, time=2015-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046537, encodeId=768f204653edc, content=<a href='/topic/show?id=7bca4923406' target=_blank style='color:#2F92EE;'>#序列表#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49234, encryptionId=7bca4923406, topicName=序列表)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce68183, createdName=xiongke010, createdTime=Wed Nov 11 18:33:00 CST 2015, time=2015-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=31797, encodeId=40c731e972b, content=第一次看专利的知识,收益了, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=01621631568, createdName=飞翔9899, createdTime=Thu Jul 09 11:04:00 CST 2015, time=2015-07-09, status=1, ipAttribution=)]
  10. [GetPortalCommentsPageByObjectIdResponse(id=56212, encodeId=36fc56212c6, content=感谢分享~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:05:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56213, encodeId=5de55621333, content=感谢分享~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:05:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56214, encodeId=8fc356214dc, content=感谢分享~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:05:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56208, encodeId=716756208a9, content=嗯,, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:04:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56209, encodeId=3d945620911, content=嗯,, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:04:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56210, encodeId=a91e56210e4, content=以前很少接触,不懂,了解下……, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:04:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56211, encodeId=86d95621130, content=以前很少接触,不懂,了解下……, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 10:04:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1704910, encodeId=1d041e04910f7, content=<a href='/topic/show?id=71742062668' target=_blank style='color:#2F92EE;'>#专利申请#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20626, encryptionId=71742062668, topicName=专利申请)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e7a30885975, createdName=zhangjingnwpu, createdTime=Fri May 29 08:33:00 CST 2015, time=2015-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046537, encodeId=768f204653edc, content=<a href='/topic/show?id=7bca4923406' target=_blank style='color:#2F92EE;'>#序列表#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49234, encryptionId=7bca4923406, topicName=序列表)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce68183, createdName=xiongke010, createdTime=Wed Nov 11 18:33:00 CST 2015, time=2015-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=31797, encodeId=40c731e972b, content=第一次看专利的知识,收益了, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=01621631568, createdName=飞翔9899, createdTime=Thu Jul 09 11:04:00 CST 2015, time=2015-07-09, status=1, ipAttribution=)]
    2015-07-09 飞翔9899

    第一次看专利的知识,收益了

    0

相关资讯

国外企业在华中药专利申请态势分析

2014年底,德国拜耳36亿元完成对滇虹药业整体收购在业界引起强烈反响。而瑞士诺华制药早在2009年就高调宣布,将针对中国市场研发中草药,并欲有条件收购中国本土药企。可见,国外企业进军中国中药市场,利用专利在目标市场进行布局正是国外企业开拓海外市场的重要手段之一。笔者试图通过分析国外申请人在中药领域的专利申请特点和技术发展趋势,为国内中药产业和企业提供参考。 需要说明的是,本文所指的中药

专利申请须知:外观设计专利申请材料

外观设计专利申请需准备的资料:应提供:外观设计产品的六面视图、立体参考图及外观设计简要说明。六面视图:主视图,后视图,左视图,右视图,俯视图,仰视图。立体参考图:能同时展示三个面的视图。简要说明:1.外观设计产品的名称;2.外观设计产品的用途;3.外观设计产品的设计要点(形状、图案、色彩);4.最能表明设计要点的图片;5.省略视图说明,透明部分的说明,基本设计的指定。

专利申请的十一大误区

随着近几年国家对知识产权的重视,国内的企业对专利在提升核心竞争力方面的作用有了进一步的认识,纷纷加强了专利工作,专利申请量大幅度增加,但是在专利代理过程中,笔者发现不少企业在专利申请过程中,仍存在误区,需要早日改进。误区一:自主研发的成果不申请专利就有知识产权。一些技术人员认为只要是自主创新,就有了自主知识产权。其实不然,专利是一种垄断权,自主研发的技术成果如果不申请专利,就得不到法律确认和保

专利申请涉及的生物材料保藏

生物技术领域,如果专利申请涉及的必须使用的生物材料是公众不能得到的,同时因文字记载有时很难描述生命实体的具体特征,为使所属技术领域的技术人员能够实施该发明,专利法规定了申请人应该保藏所使用的生物材料。 简单说,凡是在发明的技术方案中必须使用,而公众在申请日前又不能得到的生物材料,都需要保藏。 例如:大多数由自然界筛选的特定微生物和通过物理化学方法进行人工诱变所生产的新微生物应进行保藏。

带你熟悉--专利申请号

专利申请号 是指国家知识产权局受理一件专利申请时给予该专利申请的一个标识号码。 特点 一个专利申请号只可能用于一件专利申请,即使在一件专利申请或由此取得的专利权灭失之后,任何其他专利申请也不再可能使用该专利申请号。 专利申请号的组成 包括申请年号、申请种类号、申请流水号三个部分。 校验位:是1位阿拉伯数字(0至9)或大写英文字母X。 校验位位于专利申请号之后,在专利申请号与校验位之间

各国及各行业的专利申请状况

各国及各行业的专利申请状况 (摘自国家知识产权局) 随着知识经济和经济全球化深入发展,知识产权日益成为发展的重要资源和竞争力的核心要素,截至2013年,我国发明专利申请量连续3年居世界首位,知识产权对经济转型发展的推动作用不断凸显,对创新驱动发展战略的支撑作用不断增强。 如下数据可显现出近年来国家及各行业对专利的重视程度: 2014年国内发明专利受理状况: